Earn money, the shareholders want to donate!The company responded “Thank you very much” 13 times the big bull stock once again prompted the risk
On January 17, Jiu’an Medical achieved its 28th daily limit, closing at 82.81 yuan per share in late trading, a cumulative increase of more than 1280% in the past 50 trading days, and its total market value soared from 3 billion yuan to nearly 40 billion yuan. After the market closed, the company issued another stock trading risk warning announcement.
The stock price rose sharply, and shareholders were quite happy. On the interactive platform, an investor said that he was very grateful to the company’s stock price soaring for making a lot of money. He hoped that he and other profitable investors could donate to the company. The company can use this money to reward employees and make them work harder.
Remind the risk
Since 2022, Jiu’an Medical has issued stock trading risk warning announcements 4 times.
The company stated in its latest announcement on January 17 that the single-month performance of the kit product does not represent the annual performance, and the historical performance of the product does not represent future performance. The company’s stock price is currently at an all-time high, and there is a risk of a decline in the future.
At the same time, Jiu’an Medical pointed out eight major risks in terms of the uncertainty of the development of the epidemic in the United States and the uncertainty of market competition, and pointed out that the contract and order execution between the US subsidiary and the US state of New York, Massachusetts, and the US Department of Health and Human Services During the process, affected by factors such as the local epidemic situation and the company’s supply chain capabilities, there may be a risk that it may not be able to perform as scheduled or in full. The U.S. government may request to stop the execution of the contract during the execution of the contract without any reason, and cancel the subsequent purchase, and the seller shall bear the corresponding risks and possible losses.
Approved for emergency use by the FDA
Since 2022, Jiu’an Medical has continued to benefit. On the evening of January 12 and before the market on January 14, the company successively issued two major contract announcements. One stated that the U.S. subsidiary has successively received purchase orders and contracts for iHealth kits from New York and Massachusetts, with a total of more than 2.1 billion yuan. On January 13, 2019, the “Purchase Contract” was signed to sell iHealth kit products. The total contract price and tax amounted to 1.275 billion US dollars (including freight), or about 8.102 billion yuan.
On the evening of January 16, Jiu’an Medical announced that its American subsidiary New Crown Antigen Rapid Detection POC (Point Of Care) Professional Edition Kit (Colloidal Gold Immunochromatography) has obtained the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA). ). The product must be tested by a professional medical staff or a person skilled in using the product in a point of care setting to collect anterior nasal swab samples for testing. The company said that the product may bring relevant sales revenue and performance to the company in the future through emergency use authorization.
More than 100 institutions research
On the evening of January 16, Jiu’an Medical announced that more than 100 institutions will conduct online conferences to investigate the company on January 14.
Chairman Liu Yi introduced that in 2020, the company’s forehead thermometer products will participate in the public health and epidemic prevention work in China and the United States, and the iHealth brand will open up the market in the United States. With the development of the epidemic in the United States, iHealth’s new crown home self-test kit has also participated in the epidemic prevention work in the United States. The U.S. Department of Health and Human Services ordered 500 million test kits, and iHealth received 250 million orders, the largest order in its history.
In response to the production capacity problem, the company responded that China has manufacturing capacity and labor resources. In terms of raw material supply, the domestic industrial chain will export European kits in 2021 and have the ability to supply raw materials. The increase in production capacity is mainly due to the supply of labor and labor, but this takes time. At present, the company’s kit products are self-owned brands, and can seek OEM business partners in China. The company will comprehensively consider the two factors of efficiency and risk, and rationally plan production-related arrangements.
Another investor asked about the follow-up market layout of home self-testing methods in other countries. Jiu’an Medical said that the use of home new crown antigen self-test kits is more convenient than going to nucleic acid test sites. Possibility of use in other countries. However, the sensitivity of this product is lower than that of nucleic acid detection, and it is still subject to the detection methods currently approved by domestic and foreign governments.
Regarding the future market size of home self-test kits, the company said that the demand for kits is related to the development of the epidemic, and the attitude of the US government may also change according to the development of the epidemic. Investors can refer to the company’s forehead thermometer sales from 2020 to the present.
According to the 2021 semi-annual report of Jiu’an Medical, the company’s operating income in the first half of the year fell by 45.32% year-on-year to 569 million yuan. The company explained that the operating income of its epidemic-related products such as forehead thermometers and oximeters increased significantly in the same period last year, and the gross profit margin of epidemic materials exported overseas was relatively high. In this period, the sales prices of the epidemic materials and products follow the market, and the gross profit margin has decreased compared with the epidemic period.Return to Sohu, see more
Editor:
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.
.